Cancer Research CR Helping Patients Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 5041-5046, October 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bandyopadhyay, A.
Right arrow Articles by Sun, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bandyopadhyay, A.
Right arrow Articles by Sun, L.
[Cancer Research 59, 5041-5046, October 1, 1999]
© 1999 American Association for Cancer Research

Tumor Biology

A Soluble Transforming Growth Factor ß Type III Receptor Suppresses Tumorigenicity and Metastasis of Human Breast Cancer MDA-MB-231 Cells1

Abhik Bandyopadhyay2, Yong Zhu2, Michael L. Cibull, LiWei Bao, Changguo Chen and LuZhe Sun3

Department of Pharmacology [A. B., Y. Z., L. B., C. C., L. S.], Lucille P. Markey Cancer Center [L. S.], and Department of Pathology [M. L. C.], University of Kentucky College of Medicine, Lexington, Kentucky 40536

Transforming growth factor ß (TGF-ß) can promote late stage tumor progression in a number of model systems. In the present study, we have examined whether expression of a truncated soluble extracellular domain of TGF-ß type III receptor (sRIII) in human breast cancer MDA-MB-231 cells can antagonize the tumor-promoting activity of TGF-ß by sequestering active TGF-ß isoforms that are produced by the cancer cells. The secretion of sRIII reduced the amount of active TGF-ß1 and TGF-ß2 in the conditioned medium. This led to a significant reduction of the growth-inhibitory activity of the medium conditioned by sRIII-expressing cells on the growth of mink lung epithelial CCL64 cells in comparison with the medium conditioned by the control cells. The tumor incidence and growth rate of all of the three sRIII-expressing clones studied were significantly lower than those of the control cells in athymic nude mice. Four of five control cell-inoculated mice showed spontaneous metastasis in the lung, whereas none of the sRIII-expressing cell-inoculated mice had any lung metastasis. Thus, our results suggest that the sRIII may be used to antagonize the tumor-promoting activity of TGF-ß.




This article has been cited by other articles:


Home page
 Protein Eng Des SelHome page
E. V. Verona, Y. Tang, T. K. Millstead, A. P. Hinck, J. K. Agyin, and L.-Z. Sun
Expression, purification and characterization of BGERII: a novel pan-TGF{beta} inhibitor
Protein Eng. Des. Sel., July 1, 2008; 21(7): 463 - 473.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
E. C. Finger, R. S. Turley, M. Dong, T. How, T. A. Fields, and G. C. Blobe
T{beta}RIII suppresses non-small cell lung cancer invasiveness and tumorigenicity
Carcinogenesis, March 1, 2008; 29(3): 528 - 535.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. S. Turley, E. C. Finger, N. Hempel, T. How, T. A. Fields, and G. C. Blobe
The Type III Transforming Growth Factor-{beta} Receptor as a Novel Tumor Suppressor Gene in Prostate Cancer
Cancer Res., February 1, 2007; 67(3): 1090 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Ge, V. Rajeev, P. Ray, E. Lattime, S. Rittling, S. Medicherla, A. Protter, A. Murphy, J. Chakravarty, S. Dugar, et al.
Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-{beta} Type I Receptor Kinase In vivo.
Clin. Cancer Res., July 15, 2006; 12(14): 4315 - 4330.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-T. Chou and Y.-C. Yang
Post-transcriptional Control of Cited2 by Transforming Growth Factor beta: REGULATION VIA SMADS AND CITED2 CODING REGION
J. Biol. Chem., July 7, 2006; 281(27): 18451 - 18462.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. G. Kaklamani, L. Baddi, J. Liu, D. Rosman, S. Phukan, C. Bradley, C. Hegarty, B. McDaniel, A. Rademaker, C. Oddoux, et al.
Combined Genetic Assessment of Transforming Growth Factor-{beta} Signaling Pathway Variants May Predict Breast Cancer Risk
Cancer Res., April 15, 2005; 65(8): 3454 - 3461.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. De Crescenzo, P. L. Pham, Y. Durocher, H. Chao, and M. D. O'Connor-McCourt
Enhancement of the Antagonistic Potency of Transforming Growth Factor-{beta} Receptor Extracellular Domains by Coiled Coil-induced Homo- and Heterodimerization
J. Biol. Chem., June 18, 2004; 279(25): 26013 - 26018.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. L. Stenvers, M. L. Tursky, K. W. Harder, N. Kountouri, S. Amatayakul-Chantler, D. Grail, C. Small, R. A. Weinberg, A. M. Sizeland, and H.-J. Zhu
Heart and Liver Defects and Reduced Transforming Growth Factor {beta}2 Sensitivity in Transforming Growth Factor {beta} Type III Receptor-Deficient Embryos
Mol. Cell. Biol., June 15, 2003; 23(12): 4371 - 4385.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Lopez-Casillas, C. Riquelme, Y. Perez-Kato, M. V. Ponce-Castaneda, N. Osses, J. Esparza-Lopez, G. Gonzalez-Nunez, C. Cabello-Verrugio, V. Mendoza, V. Troncoso, et al.
Betaglycan Expression Is Transcriptionally Up-regulated during Skeletal Muscle Differentiation. CLONING OF MURINE BETAGLYCAN GENE PROMOTER AND ITS MODULATION BY MyoD, RETINOIC ACID, AND TRANSFORMING GROWTH FACTOR-beta
J. Biol. Chem., January 3, 2003; 278(1): 382 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Bandyopadhyay, F. Lopez-Casillas, S. N. Malik, J. L. Montiel, V. Mendoza, J. Yang, and L-Z. Sun
Antitumor Activity of a Recombinant Soluble Betaglycan in Human Breast Cancer Xenograft
Cancer Res., August 15, 2002; 62(16): 4690 - 4695.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. A. Rowland-Goldsmith, H. Maruyama, K. Matsuda, T. Idezawa, M. Ralli, S. Ralli, and M. Korc
Soluble Type II Transforming Growth Factor-{beta} Receptor Attenuates Expression of Metastasis-associated Genes and Suppresses Pancreatic Cancer Cell Metastasis
Mol. Cancer Ther., January 1, 2002; 1(3): 161 - 167.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Rowland-Goldsmith, H. Maruyama, T. Kusama, S. Ralli, and M. Korc
Soluble Type II Transforming Growth Factor-{beta} (TGF-{beta}) Receptor Inhibits TGF-{beta} Signaling in COLO-357 Pancreatic Cancer Cells in Vitro and Attenuates Tumor Formation
Clin. Cancer Res., September 1, 2001; 7(9): 2931 - 2940.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. V. Bakin, A. K. Tomlinson, N. A. Bhowmick, H. L. Moses, and C. L. Arteaga
Phosphatidylinositol 3-Kinase Function Is Required for Transforming Growth Factor beta -mediated Epithelial to Mesenchymal Transition and Cell Migration
J. Biol. Chem., November 17, 2000; 275(47): 36803 - 36810.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.